Open access · CC-BY
via OpenAlex
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
Lei Justan Zhang, Rahagir Salekeen, Carolina Soto-Palma, Qiuming Wu, Yuanjun He, Osama Elsallabi, Bilel Bdiri, Brian Hughes, Allancer Nunes, Wandi Xu, Borui Zhang, Abdalla Mohamed, Sara J. McGowan, Luise A. Angelini, Ryan D. O'Kelly
Aging Cell · 2026
Abstract
Senescent cells are a key driver of aging and contribute to many age-related diseases. Senolytics(definition), agents that selectively eliminate senescent cells, offer a promising therapeutic strategy to treat age-related diseases but face significant barriers to clinical translation. Fisetin, a natural flavonoid senolytic, has progressed to clinical trials but is limited by suboptimal efficacy and poor bioavailability. To address these challenges, we developed two novel fisetin-derived flavonoid senolytics, SR29384 and SR31133, using an integrative phenotypic drug discovery approach. These compounds exhibit enhanced senolytic activity, targeting a broad range of senescent cell types, reducing tissue senescence(definition), and improving healthspan(definition)-associated parameters in mouse models of aging. Mechanistic investigations combining transcriptomics, machine learning, network pharmacology, and molecular docking revealed that these novel senolytics may target key molecular pathways, including PARP1, CDK2, and possibly BCL-xL to selectively induce apoptosis in senescent cells. These findings provide novel senolytics with high translational potential for clinical applications in promoting healthy aging and treating age-related diseases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/acel.70736
- Canonical
- link ↗
- Fetched
- 2026-11-09 MST
Cite this
APA
Zhang, L.J., Salekeen, R., Soto-Palma, C., Wu, Q., He, Y., Elsallabi, O., Bdiri, B., Hughes, B., Nunes, A., Xu, W., Zhang, B., Mohamed, A., McGowan, S.J., Angelini, L.A., O'Kelly, R.D., Kamenecka, T.M., Niedernhofer, L.J., & Robbins, P.D. (2026). Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan. <em>Aging Cell</em>. https://doi.org/10.1111/acel.70736
Vancouver
Zhang LJ, Salekeen R, Soto-Palma C, Wu Q, He Y, Elsallabi O, et al. Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan. Aging Cell. 2026. doi:10.1111/acel.70736.
BibTeX
@article{lei2026NovelF,
title = {Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan},
author = {Lei Justan Zhang and Rahagir Salekeen and Carolina Soto-Palma and Qiuming Wu and Yuanjun He and Osama Elsallabi and Bilel Bdiri and Brian Hughes and Allancer Nunes and Wandi Xu and Borui Zhang and Abdalla Mohamed and Sara J. McGowan and Luise A. Angelini and Ryan D. O'Kelly and Theodore M. Kamenecka and Laura J. Niedernhofer and Paul D. Robbins},
journal = {Aging Cell},
year = {2026},
doi = {10.1111/acel.70736},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging cell 2026
Citation only
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.
Aging cell 2026
Open access · OA
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
Innovation in Aging 2021
Open access · CC-BY
Targeting cellular senescence with novel senotherapeutics by design to extend healthspan
Aging 2020
Preprint · CC-BY
Identification of SYK inhibitor, R406 as a novel senolytic agent
Frontiers in Pharmacology 2025
Open access · CC-BY
Editorial: Old drugs: confronting recent advancements and challenges
Molecular Metabolism 2022
Open access · CC-BY